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Insulin resistance is instrumental in the pathogenesis of
type 2 diabetes mellitus and the Insulin Resistance Syn-
drome. While insulin resistance involves decreased glucose
transport activity in skeletal muscle, its molecular basis is
unknown. Since muscle GLUT4 glucose transporter levels
are normal in type 2 diabetes, we have tested the hypothesis
that insulin resistance is due to impaired translocation of in-
tracellular GLUT4 to sarcolemma. Both insulin-sensitive
and insulin-resistant nondiabetic subgroups were studied, in
addition to type 2 diabetic patients. Biopsies were obtained
from basal and insulin-stimulated muscle, and membranes
were subfractionated on discontinuous sucrose density gra-
dients to equilibrium or under nonequilibrium conditions
after a shortened centrifugation time. In equilibrium frac-
tions from basal muscle, GLUT4 was decreased by 25–29%
in both 25 and 28% sucrose density fractions and increased
twofold in both the 32% sucrose fraction and bottom pellet
in diabetics compared with insulin-sensitive controls, with-
out any differences in membrane markers (phospholemman,





unit). Thus, insulin resistance was associated with redistri-
bution of GLUT4 to denser membrane vesicles. No effects of
insulin stimulation on GLUT4 localization were observed.
In non-equilibrium fractions, insulin led to small GLUT4
decrements in the 25 and 28% sucrose fractions and in-
creased GLUT4 in the 32% sucrose fraction by 2.8-fold over
basal in insulin-sensitive but only by 1.5-fold in both insulin-
resistant and diabetic subgroups. The GLUT4 increments in
the 32% sucrose fraction were correlated with maximal in



















therefore, represented GLUT4 recruitment to sarcolemma or
a quantitative marker for this process. Similar to GLUT4,
the insulin-regulated aminopeptidase (vp165) was redistrib-
uted to a dense membrane compartment and did not trans-
locate in response to insulin in insulin-resistant subgroups.
In conclusion, insulin alters the subcellular localization
of GLUT4 vesicles in human muscle, and this effect is im-
paired equally in insulin-resistant subjects with and without
diabetes. This translocation defect is associated with abnor-
mal accumulation of GLUT4 in a dense membrane com-
partment demonstrable in basal muscle. We have previously
observed a similar pattern of defects causing insulin resis-
tance in human adipocytes. Based on these data, we pro-
pose that human insulin resistance involves a defect in
GLUT4 traffic and targeting leading to accumulation in a
dense membrane compartment from which insulin is unable



























Insulin resistance is key to the pathogenesis of type 2 diabetes
mellitus and is also a risk factor associated with hypertension
and cardiovascular disease (1, 2). The clinical manifestations of
insulin resistance, glucose intolerance and hyperinsulinemia,
are the consequence of the inability of insulin to stimulate glu-
cose uptake in such insulin target tissues as muscle and fat. The
underlying defect must be expressed in skeletal muscle, which
accounts for 70–80% of insulin-stimulated glucose uptake in
vivo (3), and current data point to reduced glucose transport
activity, the rate-limiting step for glucose uptake (4). Hyperin-
sulinemic glucose clamp studies and limb balance studies have
consistently demonstrated impaired stimulation of muscle glu-
cose uptake in type 2 diabetes (1); however, these techniques
do not discriminate whether this is because of a reduction in
transport activity or intracellular glucose metabolism. In fact,
Bonnadonna et al., using a novel isotope tracer and limb bal-





F]2-deoxyglucose uptake during positron emission
scanning, have provided evidence for separate defects in both
transport and glucose phosphorylation in type 2 diabetes.
However, under conditions of stimulated glucose flux, investi-
gators have found that free glucose and glucose-6-phosphate
do not accumulate in skeletal muscle (4, 7–9) and that metabo-
lism within intracellular pathways can be normalized (10–12).
These latter data indicate that transport system defects likely
predominate in mediating insulin resistance. Most compelling
are ex vivo studies that show that the ability of insulin to stim-
ulate glucose transport is markedly impaired in muscle strips
and adipocytes removed from insulin resistant patients (13–16).
The molecular basis of insulin resistance remains unclear.
Insulin stimulates glucose transport via translocation of GLUT4
glucose transporter proteins from an intracellular depot to the
cell surface. In fat cells, GLUT4 expression is markedly re-
duced in type 2 diabetes and obesity (15). While other defects
may exist in insulin action pathways, GLUT4 depletion ap-
pears to be the major cause of insulin resistance in fat because
of the profound degree to GLUT4 loss and its central role in
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transport stimulation. However, in skeletal muscle, GLUT4
levels were found to be normal in multiple insulin-resistant dis-
ease states, including obesity, type 2 diabetes, impaired glu-
cose tolerance, and gestational diabetes (17, 18). This has
given rise to the inference that defects in GLUT4 translocation
cause insulin resistance in muscle (17, 18), and supportive data
are available (6, 19). Such an abnormality could arise from de-
fects in insulin signal transduction or defects in GLUT4 traffic
and targeting that lie intrinsic to the glucose transport effector
system. Investigators have demonstrated that insulin receptor
tyrosine kinase activity, together with downstream signaling
events (for example, insulin receptor substrate 1 phosphoryla-
tion, phosphatidylinositol-3 kinase activation), are reduced in
skeletal muscle (20). Thus, one potential cause of human
insulin resistance is a defect in insulin signaling that impairs
GLUT4 translocation in muscle.
The presence of signaling defects does not exclude the pos-
sibility that critical defects could lie within the glucose trans-
port apparatus. It has become clear that intracellular seques-
tration and translocation of GLUT4 are regulated by motifs
intrinsic to the GLUT4 molecule (21) together with a host of
proteins directing vesicle traffic (22–25). The complexity of
this system provides multiple potential loci for defects that
could interrupt insulin-mediated GLUT4 translocation, and
this has increased scientific interest in this area. In adipocytes
from women with gestational diabetes, we have shown that im-
paired GLUT4 translocation was associated with redistribu-
tion of GLUT4 to dense membrane vesicles in basal cells sug-
gestive of a defect in transporter trafficking or targeting (16).
However, to date, there is no evidence in muscle that defects in
GLUT4 trafficking operate as a cause of insulin resistance. In
this study, we used a biochemical approach involving subcellu-
lar membrane subfractionation of muscle, and, for the first
time, implicate defects in GLUT4 traffic and targeting as a
cause of impaired GLUT4 translocation and insulin resistance






Table I shows clinical characteristics of the study groups. We studied
subjects with normal oral glucose tolerance and patients with type 2
diabetes mellitus (26). Muscle biopsies were processed using two pro-
tocols (protocols 1 and 2) based on differences in membrane subfrac-
tionation (see below). The nondiabetic subjects in protocol 2 were
categorized as insulin sensitive or insulin resistant based on maxi-









respectively, during hyperinsulinemic euglycemic clamp studies. All
type 2 diabetic patients were being treated with sulfonylurea oral hy-
poglycemic agents, and were withdrawn from therapy for at least 3 wk
and followed on an outpatient basis. All subjects were chemically eu-
thyroid and without renal, hepatic, or cardiac disease. No subject was





After we obtained informed consent, we studied nondiabetic and un-
treated diabetic subjects on a metabolic ward where they remained
active. The subjects were allowed to equilibrate on a weight-mainte-
nance diet (28–32 kcal/kg/d), consisting of 50% carbohydrate, 35%
fat, and 15% protein. We performed standard 75-g oral glucose toler-
ance tests (26). We assessed peripheral insulin sensitivity (Table I) us-
ing the hyperinsulinemic euglycemic glucose clamp technique as pre-





/min), the overall glucose disposal rate was calculated on the
basis of the glucose infusion rate corrected for changes in glucose
pool size, assuming a distribution volume of 19% body weight and
pool fraction of 0.65. Hepatic glucose output has been shown to be
completely suppressed at the high maximally effective insulin concen-
trations achieved during the clamp (27). During the steady-state pe-





4% by monitoring serum glucose levels at 5-min inter-
vals and adjusting the infusion rate of a 20% dextrose solution. Glu-
cose uptake rates were normalized for lean body mass (excluding
bone mass) determine by whole-body, dual-energy x-ray absorptiom-
etry scanning.
We performed percutaneous needle biopsies of the vastus latera-
lis as previously described (18). In each subject, one biopsy was per-
formed under basal conditions before initiating the clamp study and a
second was performed in the contralateral leg after 3 h of steady-state
hyperinsulinemia. In some subjects, the second biopsy was performed
30 min after initiating the insulin infusion. To perform the biopsy, a
side-cutting needle (Poppler and Sons, New Hyde Park, NY) was in-










400 mg muscle tissue was retrieved. This tissue was then blot-












C. The time between the actual biopsy and snap-freezing of the












400 mg) was placed in 5 vol of




C containing 10 mM Tris-HCl, 0.25 M sucrose,
 
Table I. Clinical Characteristics
 



















































































































*Glucose uptake represents maximally insulin-stimulated rates of whole body glucose uptake assessed during hyperinsulinemic euglycemic clamps









 15 mg/kg/min, which was the median value.
 





















mol/liter fluoride. The tissue was ho-
mogenized first using a Polytron (Brinkmann, Westbury, NY) for five
5-s bursts at a setting of 5 and then with 10 up-and-down strokes of a
motor-driven Teflon pestle in a glass homogenization tube (Thomas











C for 10 min, and the supernatant was saved. The re-
sulting pellet was resuspended in the buffer, rehomogenized with the
glass homogenization tube and Teflon pestle as described above, and










C for 10 min. The resulting superna-
tant was combined with the first supernatant and together constituted
postnuclear muscle homogenate. The postnuclear homogenate was
then processed using either of two protocols for membrane subfrac-
tionation.
 
Protocol 1 (equilibrium sucrose density gradient centrifugation).
 
In each subject, postnuclear homogenates from both basal and maxi-








 for 10 min,

















membranes) was resuspended in buffer and applied to a discontinu-
ous sucrose density gradient containing 25, 28, and 32% sucrose solu-
tions, respectively. The gradient was centrifuged in a swinging-bucket








 for 16 h to achieve equilibrium separation of
membrane subfractions. Membranes were collected at each sucrose









 for 90 min. The resulting pellets (membrane subfrac-
tions) were resuspended in buffer and utilized for immunoblot analy-




C. This method is a modification of
that previously used to demonstrate insulin-mediated translocation of
glucose transporters in rat muscle (29).
 
Protocol 2 (nonequilibrium sucrose density gradient centrifuga-
tion).
 
The postnuclear homogenates from basal and insulin-stimu-
lated muscle were immediately applied to discontinuous density gra-
dients containing 25, 28, and 32% sucrose solutions, respectively.






 for 3.5 h; this shorter time interval was not sufficient to achieve
equilibrium separation of sucrose density gradient subfractions. The
sucrose solutions were then separated, diluted in buffer, and centri-








 for 90 min. The resulting pellets (membrane sub-
fractions) were resuspended in buffer and utilized for immunoblot












g membrane proteins were solubilized
in Laemmli sample buffer (30) and resolved by SDS-PAGE on 1.5-
mm slab gels containing 7.5–10% polyacrylamide. The proteins were
then electrophoretically transferred to nitrocellulose filters (31). For
immunological detection of GLUT4, nitrocellulose filters were incu-
bated with affinity-purified rabbit antiserum (1:100 dilution) specific
for the COOH-terminal segment (44 amino acids) of the GLUT4
transporter cloned from rat skeletal muscle, as previously described
(18). Three membrane marker enzymes were also analyzed by immu-
noblot in the same membrane fractions. Phospholamban is exclu-
sively localized to sarcoplasmic reticulum, and was measured using
affinity-purified rabbit antibodies against the canine protein at 1:5,000
dilution (32). Phospholemman was studied as a marker for sarco-
lemma since it is a chloride channel densely distributed throughout
cell surface membranes in cardiac muscle (33, 34). Anti–phospholem-
man antibodies were raised in rabbits against a COOH-terminal pep-














-tubule membrane marker using an mAb
(Novus Molecular, Inc., San Diego, CA) at 1:1,000 dilution (35). In
addition, the insulin-regulated aminopeptidase (IRAP) or vp165 (36)









g/ml dilution), kindly supplied by Dr. S.
Keller (Dartmouth College). IRAP is a vesicle protein known to be a
constituent of GLUT4-containing vesicles (36, 37). Immunoreactivity





I]protein A, while the immunoreactivity for DHP and
IRAP was identified by an enhanced chemiluminescence system
(ECL; Amersham Corp., Arlington Heights, IL). Cross-reacting pro-
teins were quantified by autoradiography and scanning densitometry
(Molecular Dynamics, Sunnyvale, CA). Parallel experiments were
performed to show that each signal in individual subjects was in the
linear range of correlation between signal density and amount of pro-
tein loaded on gels. A quantitative comparison among the different
gels was made possible by including five internal standard lanes on




g membrane samples from two




g of crude rat muscle
membrane proteins.
 
Other assays and statistics
 
Plasma glucose was measured by the glucose oxidase method with a
glucose analyzer (YSI 2300; Yellow Springs Instruments, Yellow
Springs, OH). Serum insulin levels were measured using a microparti-
cle enzyme immunoassay kit (Abbott Diagnostics, Chicago, IL). Pro-
tein was measured by the Coomassie brilliant blue method described














Protocol 1: Equilibrium-density gradient separation of muscle
membrane subfractions. 
 
To examine whether glucose trans-
port system defects contribute to insulin resistance in type 2 di-
abetes, we initially studied five lean control subjects and four
untreated diabetic patients. As shown in Table I (protocol 1),
the mean age in the control and diabetic subgroups was simi-
lar; however, the diabetic patients were obese and exhibited
fasting hyperglycemia and hyperinsulinemia. Maximally insu-
lin-stimulated glucose uptake rates assessed using the eu-
glycemic clamp technique were reduced by 54% in the diabetic









In each subject, vastus lateralis biopsies were obtained un-
der basal conditions and at steady-state serum insulin concen-
trations that maximally stimulate the glucose transport system.
Muscle membranes were subfractionated on sucrose density
gradients centrifuged overnight to obtain equilibrium separa-
tion of subfractions. Fig. 1 shows membrane distribution of
GLUT4 in muscle obtained under basal conditions. In type 2
diabetes, the relative amounts of GLUT4 were decreased by









 NS). These decrements corresponded with
















 0.05) compared with con-
trols. Thus, in basal muscle, a greater proportion of GLUT4
was localized in denser membrane fractions in type 2 diabetes.
The total tissue content of GLUT4, determined by immuno-
blot analysis of total membrane fractions (for example, post-
nuclear homogenate), was similar in the diabetic and non-






 NS; data not shown) as
previously reported (17, 18).
The observation that GLUT4 was abnormally localized to




Abbreviations used in this paper:
 
 DHP, dihydropyridine-binding






generalized effects on protein recovery or to nonspecific
changes in membrane composition. To address these possibili-
ties, we measured total protein in the postnuclear homogenate
and each of the membrane fractions, together with phos-
pholemman, a marker for sarcolemma (33, 34), and phospho-
lamban, a marker for sarcoplasmic reticulum (32). Table II de-
lineates data showing recovery of protein and membrane
markers. In comparing control and diabetic subgroups, there
were no statistically significant differences in the recovery of







 NS). Thus, major changes in protein re-
covery or in the subfractionation of sarcolemmal and intracel-
lular membranes could not explain differences in the distribu-
tion of GLUT4 in basal muscle.
Muscle biopsies were also obtained in the presence of max-
imal steady-state serum insulin concentrations and processed
as described for protocol 1. In both controls and diabetes, insu-
lin did not affect the amount of GLUT4 in any of the sucrose






 NS; data not shown) when
compared with basal data (see Fig. 1). Recoveries of protein,







 NS; data not shown). In these subjects
(Table I, protocol 1), the second biopsy was performed after
3 h of insulin stimulation during the clamp study. In two addi-
tional controls, the second biopsy was obtained 30 min after
initiating the insulin infusion, and again, no effect of insulin
was observed in these membrane subfractions (data not
shown). Thus, insulin-mediated GLUT4 translocation could
not be detected in membrane subfractions obtained from su-
crose density gradient fractions at equilibrium following pro-
longed centrifugation.
 
Protocol 2: Non–equilibrium-density gradient separation of
muscle membrane subfractions. 
 
In another series of experi-
ments, we prepared sucrose density membrane fractions under
non-equilibrium conditions (for example, after a shortened
centrifugation period). Muscle biopsies were obtained from a
greater number of subjects with normal glucose tolerance to
assess glucose transport system defects occurring in the ab-
sence of diabetes. These subjects were designated as insulin
sensitive or insulin resistant based on maximally insulin-stimu-








 the median value of 15 mg/
kg/min. As shown in Table I, these two nondiabetic subgroups
were well matched for mean age and body mass index; how-
ever, insulin-sensitive subjects were found to have mean maxi-







 0.01). Seven type 2 diabetic pa-
Figure 1. Distribution of GLUT4: equilib-
rium separation of sucrose density mem-
brane subfractions from basal skeletal mus-
cle. Skeletal muscle biopsies were obtained 
from insulin-sensitive nondiabetic controls 
(closed bars) and from type 2 diabetic 
(DM) patients (open bars) under basal con-
ditions. Muscle was homogenized and sub-
fractionated on discontinuous sucrose gra-
dients until equilibrium separation was 
achieved. Membrane proteins from each 
subfraction (50 mg) were resolved by SDS-
PAGE, and reacted with GLUT4 antibod-
ies followed by [125I]protein A. Relative 
amounts of GLUT4 were quantified by au-
toradiography and densitometry, and data 
represent mean6SE of subgroups delin-
eated in Table I (protocol 1). *P , 0.05 for 
DM versus controls.
 
Table II. Protocol 1: Percent Recovery of Protein and 
Membrane Markers in Muscle Membrane Subfractions
 
Sucrose gradient fraction





61.5 3.560.6 2.960.9 20.462.3
Type 2 diabetes 9.062.4 3.060.9 3.260.7 19.162.1
Phospholemman recovery*
Controls 27.164.0 17.865.9 12.964.1 7.261.6
Type 2 diabetes 30.065.6 13.863.0 14.865.8 6.261.8
Phospholamban recovery*
Controls 17.462.4 10.562.7 11.464.2 10.664.3
Type 2 diabetes 16.162.3 10.763.6 14.164.1 7.361.6
*Data represent percent recovery in the membrane fractions of the total
present in post-nuclear homogenates. Density gradient subfractions
were retrieved after equilibrium separation of membranes (see protocol
1). Muscle biopsies were obtained under basal conditions.
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tients were also studied with higher mean age and body mass
index; they were uniformly insulin resistant.
As before, muscle biopsies were obtained under basal and
hyperinsulinemia conditions, however, the major change from
protocol 1 was that sucrose density gradients were centrifuged
for only 3.5 h and subfractions retrieved before equilibrium
separation. Relative amounts of GLUT4 were assessed in each
membrane subfraction, and an immunoblot from an insulin-
sensitive subject is shown in Fig. 2. Fig. 3 shows mean GLUT4
amounts detected in the 25 and 32% sucrose gradient frac-
tions, respectively, in all subjects. Insulin infusion produced
small (12–13%) GLUT4 decrements in the 25% sucrose frac-
tion that were not statistically significant (all subgroups P 5
NS). In the 32% sucrose fraction, insulin increased GLUT4,
however, the response was notably different among the sub-
groups. In the insulin-sensitive subgroup, insulin led to a two-
fold increase in mean GLUT4 levels in the 32% sucrose frac-
tion (P , 0.01). In both insulin-resistant and type 2 diabetic
subjects, the amounts of GLUT4 in the 32% fraction from in-
sulin-stimulated muscle were not significantly different from
basal GLUT4 levels (P 5 NS). GLUT4 data (not shown) in
the 28% fraction paralleled results observed in the 25% frac-
tion (mean basal and insulin-stimulated values were 10.560.9
and 10.160.8 U/mg membrane protein in insulin-sensitive sub-
jects, 10.361.7 and 8.861.8 in insulin resistant, and 6.661.2
and 6.961.1 in type 2 diabetic subgroups), whereas data in the
bottom pellet were analogous to those in the 32% fraction
(mean basal and insulin-stimulated values were 1.560.5 and
3.160.8 in insulin sensitive, 2.260.5 and 2.460.6 in insulin-
resistant patients, and 4.060.9 and 4.061.1 in diabetes). These
differences in GLUT4 localization could not be explained by
nonspecific or generalized effects on membrane subfraction-
ation, as demonstrated in Table III. Recoveries of protein,
phospholemman, phospholamban, and the a-1 subunit of the
DHP (t-tubule marker) were similar among insulin sensitive,
insulin resistant, and type 2 diabetic subgroups in each sucrose
gradient fraction from both basal and insulin-stimulated mus-
cle (P 5 NS). 
Figure 2. Immunoblot of 
GLUT4 glucose transporters in 
muscle membranes: effects of in-
sulin in non-equilibrium sucrose 
density membrane subfractions. 
Muscle biopsies were obtained 
under basal and insulin-stimu-
lated conditions from an insulin-
sensitive individual. Muscle was 
homogenized and subfraction-
ated on discontinuous sucrose 
gradients under non-equilib-
rium conditions with a shortened 
centrifugation time. Membrane 
proteins (50 mg) from each
subfraction were resolved by 
SDS-PAGE, and reacted with 
GLUT4 antibodies followed by 
[125I]protein A. The figure repre-
sents an autoradiograph. The lo-
cation of molecular weight 
markers is shown on the right.
Figure 3. Effects of insulin on GLUT4 in mus-
cle membrane subfractions from insulin-sensi-
tive, insulin-resistant, and type 2 diabetic sub-
groups. Muscle biopsies were obtained under 
basal (closed bar) and insulin-stimulated (open 
bar) conditions from insulin sensitive (IS) and 
resistant (IR) subjects based on maximal glu-
cose disposal rates . or , 15 mg/kg lean body 
mass/min, respectively. Type 2 diabetics (DM) 
were also studied. Non-equilibrium sucrose 
density membrane subfractions were obtained, 
and subjected to immunoblot analyses as de-
scribed for Fig. 2. GLUT4 was quantified by 
autoradiography and densitometry, and 
mean6SE levels are shown in the 25% (left) 
and 32% (right) sucrose density subfractions 
corresponding to subgroups delineated in Ta-
ble I (protocol 2).
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GLUT4 vesicles also contain IRAP or vp165, which trans-
locates together with GLUT4 to the cell surface (36, 37). To
further test for abnormalities in GLUT4 vesicle traffic, relative
amounts of IRAP were assessed in the muscle membrane sub-
fractions by immunoblot analysis; the data are shown in Table
IV. The data generally demonstrate the same two abnormali-
ties in insulin resistant subgroups that were observed for
GLUT4. First in basal muscle, 2.6–4.3 times more IRAP is lo-
calized in denser membrane vesicles recovered in the bottom
pellet of the gradient in both insulin-resistant and diabetic sub-
groups than in insulin-sensitive subjects. Second, in insulin-
sensitive subjects, insulin increased IRAP by 1.85-fold in the
28% sucrose fraction, whereas this effect was absent in both
insulin-resistant nondiabetic and diabetic subgroups. Thus,
similar to GLUT4, IRAP is redistributed to a denser mem-
brane compartment and does not translocate in response to in-
sulin in insulin resistant subjects. The discrepancy that insulin
augments GLUT4 in the 32% sucrose fraction and IRAP in
the 28% fraction in the insulin sensitive subgroup may be ex-
plained by the fact that not all cellular GLUT4 is located in
IRAP-containing vesicles (39, 40) and/or that different func-
tional pools of intracellular GLUT4 vesicles contain variable
amounts of IRAP relative to GLUT4 (41). 
The GLUT4 increment in the 32% fraction is a quantitative
marker for insulin sensitivity. To examine the relationship be-
tween GLUT4 changes in the 32% fraction (protocol 2) and
insulin sensitivity, we calculated the insulin-mediated increase
over basal in each individual subject. Mean data are shown in
Fig. 4. The GLUT4 increment in the insulin sensitive group
was 2.82-fold, which represents a 182% increase over basal val-
ues; this was approximately three times higher (P , 0.01) than
the 54% increase in insulin-resistant subjects (1.54-fold) and
the 63% increase in Type 2 Diabetes (1.63-fold). Thus, the
ability of insulin to augment GLUT4 in the 32% fraction was
markedly impaired even in normoglycemic insulin-resistant in-
dividuals, and could not be attributed to antagonistic effects of
hyperglycemia on insulin action (4, 42) (for example, “glucose
toxicity”). To assess the relationship between the insulin effect
in the 32% fraction and glycemia-independent insulin resis-
tance, the GLUT4 increment was correlated with the maxi-
mally stimulated glucose uptake rate in nondiabetic subjects
(for example, insulin-sensitive plus -resistant subjects). Fig. 5
shows that there was a positive and statistically significant cor-
relation between these two variables. Two aspects of the data
indicate that the association between insulin resistance and
low GLUT4 increment was independent of obesity. First, BMI
was not correlated with GLUT4 increment (P 5 NS), and, sec-
ond, the GLUT4 increment was found to be greater in insulin
sensitive than in insulin-resistant subjects (Fig. 4) despite the
fact that these subgroups were well matched for body mass in-
dex (Table I).
Discussion
In this study, sucrose density gradients were used to separate
membrane subfractions under two conditions, at equilibrium
and under non-equilibrium conditions after a shortened cen-
trifugation time. Data using membrane fractions obtained un-
der non-equilibrium conditions demonstrated that insulin aug-
ments GLUT4 by 2.8-fold in one sucrose gradient fraction
(32% sucrose), concomitant with a trend towards reduction in
other fractions (25% and 28% sucrose) in insulin-sensitive in-
dividuals. These observations support the conclusion that insu-
lin stimulates glucose transport via translocation of GLUT4 to
sarcolemma in human muscle. 
Investigators have relied on either subcellular membrane
Table III. Protocol 2: Percent Recovery of Protein and 
Membrane Markers in Muscle Membrane Subfractions
Sucrose gradient fraction
25% 28% 32% Pellet
Protein recovery*
Insulin-sensitive 4.960.8 3.461.2 2.260.5 4.661.0
Insulin-resistant 4.460.7 2.760.3 2.660.4 5.761.0
Type 2 diabetes 3.960.7 2.260.3 2.661.0 4.861.0
Phospholemman recovery*
Insulin-sensitive 2866 1264 863 762
Insulin-resistant 3069 1263 1264 663
Type 2 diabetes 2764 1463 862 963
Phospholamban recovery*
Insulin-sensitive 1062 1061 561 962
Insulin-resistant 1161 1164 662 1064
Type 2 diabetes 1264 1263 662 963
DHP*
Insulin-sensitive 1861 3163 1662 962
Insulin-resistant 2161 3663 1663 862
Type 2 diabetes 1662 3063 1662 1061
*Data represent percent recovery in the membrane fractions of the total
present in postnuclear homogenates. Density gradient subfractions were
retrieved before equilibrium separation of membranes could occur (see
protocol 2). Data from basal and insulin-stimulated muscle were similar
and were combined to obtain the mean values.
Table IV. Effects of Insulin on the IRAP (vp165) in Muscle 
Membrane Subfractions from Insulin-sensitive,
Insulin-resistant, and Type 2 Diabetic Subgroups
Sucrose gradient fraction
25% 28% 32% Pellet
Insulin-sensitive
Basal 6.566 3.360.5 3.461.1 3.861.2
Insulin 5.261.1 6.161.3* 3.961.3 3.860.7
Insulin-resistant
Basal 3.360.9 4.460.8 4.061.0 9.761.2‡
Insulin 3.660.7 4.661.1 4.861.0 10.266‡
Type 2 diabetics
Basal 3.260.8 4.560.4 5.260.6 16.361.3‡
Insulin 3.960.8 4.460.7 4.760.4 17.863.2‡
Skeletal muscle biopsies were subjected to non-equilibrium sucrose
density membrane subfractionation (protocol 2), and subfractions were
subjected to immunoblot analysis using antibodies against IRAP. The
data represent the mean6SE of relative levels in the various subgroups.
*P , 0.05 when compared with value in basal muscle from insulin-sensi-
tive subjects. ‡P , 0.05 when compared with values in the pellet from in-
sulin-sensitive subjects.
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fractionation or immunocytochemistry of basal and insulin-
stimulated muscle to resolve GLUT4 translocation. Subcellu-
lar fractionation of skeletal muscle has proven much more
difficult than it has in adipocytes; the effectiveness of this
biochemical approach in muscle has been limited by poor re-
covery of membrane markers, a high degree of contamination
among membrane subfractions, and lack of a marker that de-
fines the intracellular pool. In rat muscle, several groups of
investigators have persevered and obtained generally concor-
dant data showing that insulin leads to two- to threefold en-
richment of transporters in a sarcolemma-enriched fraction
and a decrease in these parameters in microsomes (29, 43, 44).
Biochemical study of human muscle is more limited. In our ex-
periments using membranes subfractionated to equilibrium,
insulin stimulation did not affect GLUT4 distribution in con-
trol or diabetic subjects, and translocation was not apparent,
suggesting that GLUT4 donor and acceptor membranes are
both present in the same fractions. Similarly, Lund et al. (45)
failed to demonstrate insulin-mediated GLUT4 translocation
in both non-diabetic controls and type 2 diabetic patients.
Guma et al. (46) were later able to show highly variable re-
sponses with a mean 60% GLUT4 increase in one sucrose den-
sity membrane subfraction together with 50% decrease in
another in muscle from normoglycemic individuals. The im-
munocytochemical approach has demonstrated recruitment of
intracellular GLUT4 to sarcolemma in both rats and humans
(4), although there has been controversy regarding the intra-
cellular localization in basal muscle (for example, tubulovesic-
ular structures, subsarcolemmal vesicles, transverse tubules
and terminal cisternae-triads). In humans, Friedman et al. (47)
used immunogold EM to show that insulin moved GLUT4
from tubulovesicular structures and triads to sarcolemma, and
Kelley et al. (6), using confocal laser scanning microscopy
found that insulin doubled GLUT4 label at sarcolemma. Thus,
despite some points of controversy and inconsistency, previous
data point to GLUT4 translocation as an important mecha-
nism of transport stimulation in human muscle.
The current data also provide biochemical evidence that
Figure 4. Insulin-mediated increase in GLUT4 in the 32% sucrose 
density membrane subfraction. The GLUT4 increment in the 32% 
sucrose density membrane subfraction from insulin-stimulated mus-
cle was calculated as fold increase over basal in each individual (see 
Fig. 3). Data represent the mean6SE of increments in muscle from 
insulin-sensitive (IS), insulin-resistant (IR), and type 2 diabetic (DM) 
individuals. **P , 0.01 compared with IS.
Figure 5. The relationship between the 
GLUT4 increase in the 32% sucrose den-
sity membrane fraction and insulin sensitiv-
ity. In muscle from individual normoglyce-
mic subjects (IS and IR from Fig. 4), the 
fold increase in GLUT4 (insulin-stimulated 
over basal) in the 32% sucrose density 
membrane subfraction was correlated with 
the maximally stimulated in vivo glucose 
disposal rate normalized per kilogram lean 
body mass.
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impaired GLUT4 translocation in muscle can explain human
insulin resistance. Such a translocation defect has been in-
ferred as a cause of human insulin resistance, without much
supportive empirical data, ever since muscle GLUT4 expres-
sion was found to be normal in these patients (17, 18). Insulin’s
ability to increase GLUT4 in the 32% sucrose fraction was sig-
nificantly correlated with maximally-stimulated glucose dis-
posal rates, an in vivo measure of insulin sensitivity that largely
reflects insulin action in muscle. Thus, the GLUT4 increase in
the 32% sucrose fraction either represents GLUT4 recruit-
ment to sarcolemma or is a quantitative marker for this pro-
cess. When the data were considered in the context of subject
subgroups, the insulin-mediated GLUT4 increment was mark-
edly reduced in both insulin-resistant and type 2 diabetic indi-
viduals (z 1.5-fold above basal) when compared with the 2.8-
fold increase in insulin-sensitive subjects. These differences
were not accompanied by differences in organelle marker pro-
teins in the various membrane subfractions, indicating that the
abnormalities were specific for GLUT4. The data demonstrate
a defect in insulin-mediated GLUT4 translocation that is
equally severe in insulin-resistant patients with and without di-
abetes. Recent reports indicate that more intracellular GLUT4
may translocate to t-tubule membranes than surface sarco-
lemma (48–50). The 32% sucrose fraction contains ample
quantities of the protein marker for t-tubules as well as phos-
pholemman which is densely distributed along sarcolemma in
cardiac muscle (33, 34), but so do other fractions. The data im-
ply that GLUT4 is recruited to a particular domain of sarco-
lemma that is enriched in the 32% sucrose fraction under these
conditions, and this step is impaired in insulin-resistant sub-
jects.
The current biochemical results are consistent with recent
immunocytochemical data reported by Kelley et al. (6), who
showed reduced GLUT4 staining associated with sarcolemma
following insulin stimulation in obese and type 2 diabetic pa-
tients. However, our data indicate that the translocation defect
is not a function of obesity since insulin sensitive and resistant
subgroups were well-matched for body mass index and percent
body fat. Zierath et al. (19) observed a 1.6-fold GLUT4 in-
crease in a plasma membrane fraction from nondiabetic con-
trols but no effect of insulin in type 2 diabetics. The current
data, using non-equilibrium membrane subfractions, show a
much larger increment (2.8-fold) in insulin-sensitive nondia-
betics. Analysis of the current data, together with those of
Kelley et al. (6) and Zierath et al. (19), illustrates an important
point when studying insulin resistance in nondiabetic and dia-
betic subjects. There are large individual differences in insulin
sensitivity among normoglycemic “controls,” and this varia-
tion is largely independent of measures of generalized obesity
(for example, both lean and obese subjects can be either very
insulin sensitive or resistant) (51–53). Therefore, nondiabetic
subjects should not be considered as a homogeneous group in
comparison with type 2 diabetic patients, and obesity cannot
effectively be used to identify which nondiabetic subjects are
insulin resistant. One explanation for the larger insulin effect
(2.8-fold GLUT4 increment in the insulin-sensitive subgroup)
is that we have defined a control group on the basis of insulin
sensitivity distinct from insulin-resistant nondiabetics. The
translocation defect in the current paper is pertinent to the
larger obesity-independent component of insulin resistance.
Furthermore, the study of separate insulin-sensitive, -resistant,
and diabetic subgroups can distinguish defects induced by hy-
perglycemia. The translocation defect associated with insulin
resistance cannot be attributed to effects of hyperglycemia or
“glucose toxicity” (4, 42), since it is equally severe in the nor-
moglycemic insulin resistant and type 2 diabetic subgroups.
Thus, impaired translocation could contribute to insulin resis-
tance in prediabetic individuals and contribute to the insulin
resistance syndrome (for example, syndrome X) (1). The rele-
vance of the translocation defect to the pathogenesis of the in-
sulin resistance syndrome is a hypothesis deserving further
study.
An additional important observation was that the translo-
cation defect was accompanied by a second abnormality in
GLUT4 subcellular localization demonstrable even in basal
muscle. This novel abnormality was clearly observed after
equilibrium separation of sucrose density membrane subfrac-
tions but was also evident in the experiments using non-equi-
librium subfractions. Greater amounts of GLUT4 were tar-
geted to dense membrane vesicles (recovered in the 32%
sucrose fraction and bottom pellet), and lesser amounts recov-
ered in lighter vesicles (recovered in 25 and 28% sucrose frac-
tions), in insulin-resistant subgroups compared with insulin-
sensitive controls. This accumulation of GLUT4 in denser
membrane vesicles was specific for GLUT4 and did not affect
sarcolemma and sarcoplasmic reticulum membrane markers.
A similar pattern of abnormalities in insulin-resistant subjects
was observed for IRAP (or vp165), a constituent of GLUT4-
containing vesicles (36, 37). In basal muscle from both insulin
resistant nondiabetic and diabetic individuals, IRAP was redis-
tributed to dense membrane vesicles recovered in the sucrose
gradient pellet relative to that observed in the insulin-sensitive
subgroup. In addition, insulin was able to augment IRAP in
the 28% sucrose fraction in the insulin-sensitive subjects but
had no effect in the insulin resistant subgroups. An important
difference in insulin-sensitive subjects was that insulin in-
creased GLUT4 in the 32% fraction and IRAP in the 28%
fraction. The data do not explain the reason for this difference.
However, it is known that different functional pools of intra-
cellular GLUT4 vesicles in rat skeletal muscle and other cells
contain variable proportions of IRAP relative to GLUT4 (39–
41). These observations provide possible explanations of why
translocation of IRAP and GLUT4 were resolved in different
sucrose density fractions. In general, the data are complemen-
tary. The important points are that GLUT4 and IRAP accu-
mulated in or were targeted to a dense membrane compart-
ment, and this abnormality was associated with a defect in
insulin-mediated translocation in insulin-resistant subjects.
This combination of defects in GLUT4 traffic and targeting
and translocation is analogous to a pattern we have previously
observed in human adipocytes. In insulin-resistant omental ad-
ipocytes from women with gestational diabetes mellitus, a
much greater proportion of cellular GLUT4 was localized in
dense membrane vesicles (cofractionating with plasma mem-
branes and high-density microsomes) in basal cells compared
with that in nondiabetic gravidas, and there was little or no
GLUT4 recruitment from microsomes to plasma membrane in
response to insulin (16). In subcutaneous adipocytes from type
2 diabetic patients, it is difficult to accurately assess subcellular
trafficking due to the profound reduction in GLUT4 expres-
sion (15). More recently, we (54) have been able to localize
GLUT4 vesicles in membrane fractions via study of IRAP (36,
37). In adipocytes from normal controls, IRAP and GLUT4
were observed to translocate from low-density microsomes to
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plasma membrane in response to insulin. In contrast, in diabe-
tes, IRAP accumulated in vesicles cofractionating with plasma
membrane and high-density microsomes, and this was associ-
ated with impaired insulin-mediated translocation of IRAP.
Based on current and previous data, we propose that a defect
in GLUT4 trafficking and targeting causes human insulin resis-
tance and is common to both skeletal muscle and adipocytes.
This defect leads to GLUT4 accumulation in a dense mem-
brane compartment from which transporters are unable to be
recruited to cell surface membranes. This mechanism of insu-
lin resistance is operative in adipocytes but is relegated to
secondary importance by a profound reduction in GLUT4
expression in type 2 diabetes. However, this mechanism pre-
dominates in skeletal muscle where normal expression of
GLUT4 is maintained.
In the current experiments, the non-equilibrium sucrose
density gradient fractions show a high degree of cross contami-
nation for sarcolemma (phospholemman), sarcoplasmic reticu-
lum (phospholamban), and t-tubule (a-1 subunit of the dihy-
dropyridine binding complex) markers. Even though there is
extensive overlap of marker proteins, we have defined experi-
mental conditions in human muscle showing that (i) under
basal conditions, GLUT4 accumulates or is redistributed to a
dense membrane compartment in insulin resistant individuals
compared with insulin sensitive subjects; and (ii) in response to
insulin, specific changes in GLUT4 localization are correlated
with glucose uptake activity and are impaired in insulin resis-
tant subjects. The data constitute strong operational evidence
for combined defects in GLUT trafficking and translocation in
skeletal muscle as a cause for human insulin resistance.
The biochemical basis of defects in GLUT4 trafficking re-
mains to be defined. A translocation defect per se could be due
to either impaired insulin signal transduction or lie intrinsic to
the glucose transporter effector system. Reduced insulin re-
ceptor tyrosine kinase activity, phosphorylation of insulin re-
ceptor substrate-1, and activation of PI-3-kinase have been
observed in skeletal muscle from obese and type 2 diabetic pa-
tients (20). While signal transduction abnormalities may be
contributory, it should be emphasized that the translocation
defect is associated with accumulation of GLUT4 in dense
membrane vesicles in basal tissue. Thus, the defect in cellular
targeting or trafficking of GLUT4 is independent of insulin.
The clear implication is that the abnormality in basal GLUT4
targeting and trafficking is a distinct defect intrinsic to the glu-
cose transport system, which is then mechanistically linked to
impaired translocation. This is in contrast to other known cel-
lular (55) and animal models (42, 56) of insulin resistance that
involve isolated translocation defects without evidence that
GLUT4 trafficking is disturbed under basal conditions. GLUT4
vesicle trafficking is constitutive, highly regulated, multicom-
partmental (4, 21), and involves multiple proteins that also di-
rect exocytosis and endocytosis of synaptic neurosecretory ves-
icles (22–25). It is, therefore, feasible that defects at any of
several steps could alter trafficking and targeting of GLUT4 to
produce the novel pattern of abnormalities observed in human
skeletal muscle. It will be important to elucidate molecular
mechanisms leading to GLUT4 accumulation in denser mem-
brane vesicles, the identity of this membrane compartment,
and how this alteration impairs translocation in response to in-
sulin. These defects would have important implications for
both treatment and prevention of type 2 diabetes and the insu-
lin resistance syndrome.
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